Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials TO THE EDITOR: Tsodikov and colleagues' article (1) has a major flaw: The authors do not account for overdiagnosis caused by prostate-specific antigen (PSA) testing. They introduce mean lead time (MLT), a new and nonvalidated metric designed to encompass the process of early detection and diagnosis of cancer in different populations. Because some cases of cancer are detected by screening, MLT is confounded with the well-known screening biases, of which overdiagnosis is an important contributor. Without adjustment for overdiagnosis (a clear harm), MLT is a flawed metric for determining screening benefit and not a substitute for the definitive end point of screening: mortality from the disease. Tsodikov and colleagues' article does not indicate that such an adjustment was done. The mortality end point is encapsulated in Pinsky and associates' article (2) , which documents the lack of benefit from organized screening as performed in the intervention group of the PLCO (Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial) compared with the opportunistic screening that took place in the control group. Further, Tsodikov and colleagues (1) do not note the remarkable major discrepancies between the different components of the ERSPC (European Randomized Study of Screening for Prostate Cancer), which have never been satisfactorily explained (3) .
That the authors did not account for treatment data in their analysis is particularly notable. Screening can reduce mortality only if at least some cases of cancer are detected early and their outcome is improved because of being treated earlier than they would have been without screening. Screening benefit and treatment are inextricably connected. Whatever the true relationship between PSA screening and reduction of prostate cancer mortality, it cannot be accurately determined using MLT because this metric does not include characteristics of cancer or treatment information and the interrelationship between the two. The authors thus could not adjust for the treatment imbalance reported in the ERSPC (3) and have probably overestimated any benefit from this trial.
Their analysis does not justify their conclusion that the ERSPC and PLCO provide similar evidence that PSA screening reduces mortality. In summary, their article provides no reason to ignore the recommendation of the U.S. Preventive Services Task Force (4) against PSA-based screening for prostate cancer in all age groups and to assume benefits in the PLCO equivalent to those averred in the ERSPC. TO THE EDITOR: Tsodikov and colleagues (1) present a complex reanalysis of the PLCO and ERSPC trials based on screening intensity. This factor in each of the 4 randomization groups was estimated using the MLT, which quantifies by how long the diagnosis of prostate cancer has been advanced. The variable of randomization group in Cox models was then replaced by the value of the MLT found for each group. We believe that this statistical approach is incorrect.
Philip
We are aware of no other trial in which the variable of randomization group was replaced by one representing a value calculated according to the few participants diagnosed with the disease in question. This replacement equates to assigning participants never affected by prostate cancer a statistical quantity that is entirely specific of participants diagnosed with this condition. A strange consequence is the assignment of a time variable of at least 1.6 years to those who were no longer in the trial after the first 1.6 years because of such factors as death.
Overdiagnosis substantially influences the results of Table 2 (1). The MLT is a mix of clinical lead time associated with the early detection of cases of potentially deadly cancer and length of time associated with the detection of cases of cancer that would never have been diagnosed clinically during the participant's lifetime. Overdiagnosis does not affect the risk for death from prostate cancer, but the amount of overdiagnosis depends largely on how screening is performed. Restrained overdiagnosis would have led to MLTs shorter than 4 years in groups invited to screening, whereas more overdiagnosis would have led to longer MLTs. The direct consequence of variable amounts of overdiagnosis is that hazard rates derived from Cox models could correspond to a wide range of values, from nearly no decrease in risk for death from prostate cancer to considerable risk reductions. A paradoxical consequence is that the greater the level of overdiagnosis (and thus the longer the MLT in screening groups), the smaller the apparent risk for death from prostate cancer obtained from Cox models (that is, a hazard ratio > 0.92 [ Table 1 of their article, screening decreased prostate cancer deaths by 9 (95% CI, Ϫ15 to Ϫ3) per 10 000 persons in the ERSPC and increased it by 1 (CI, Ϫ7 to 8) per 10 000 persons in the PLCO. These results suggest a small reduction in prostate cancer mortality in the former and no clear evidence of such in the latter. A complication in the interpretation of the results of the PLCO is that routine PSA testing in the control group started at 33% and increased to 46% in 5 years (2), which biased the estimated effect of prostate cancer mortality toward 0, and that follow-up took place after the last screening, which increased variability. Complicating the interpretation of the results of the ERSPC is a stage-specific imbalance in therapy between randomization groups (3) that is larger than that in the PLCO (4), suggesting a possible bias in treatment choice.
In their combined analysis of the ERSPC and PLCO, Tsodikov and colleagues (1) replaced randomization group with MLT, a procedure that can lead to bias. Bias can arise because persons screened contribute more to MLT than those not screened, the PLCO had more control group screening than the ERSPC, and the background rate of prostate cancer mortality (in the absence of screening) may have differed between control participants who were and were not screened analogous to rates of breast cancer mortality substantially differing between participants who decline screening and control participants in a mammography trial (5) . Bias can also arise because the ERSPC had a lower PSA threshold for biopsy than the PLCO, and MLT depends on this threshold. The ERSPC was consequently more likely than the PLCO to detect cases of overdiagnosed prostate cancer that increase MLT without contributing to a reduction in prostate cancer mortality.
Tsodikov and colleagues (1) also reported the risk reduction in prostate cancer rather than a difference in prostate cancer mortality rates. Reporting relative rather than absolute reduction makes weighing harms and benefits and communicating effectively to patients difficult. 
TO THE EDITOR:
We read Tsodikov and colleagues' article (1) with interest. Of the 2 prostate screening trials ERSPC and PLCO, the latter experienced the most contamination. With only 7 years of follow-up, 85% of the screening group actually received PSA screening and 52% of the control group were screened by the sixth year. The authors of the PLCO stated later (2) that their study should not be interpreted as a trial of screening versus no screening but rather as one of annual screening versus "usual care"; at the time the study was initiated, PSA screening was ubiquitous.
Tsodikov and colleagues' study (1) sought to remove the contamination found in the PLCO's control group and actually does compare screening versus no screening. Despite the limitations in MLT metrics, the authors have shown that screening does reduce prostate cancer mortality and use data from the PLCO to place this study on a more similar playing field as the ERSPC.
To support the authors' findings, a post hoc analysis in 2012 of men with little to no comorbidity in the PLCO (3) showed a 44% reduction in the risk for prostate cancer mortality among participants in the screening group (hazard ratio, 0.56 [95% CI, 0.33 to 0.95]) despite the contamination in the usual care group. The median age of men in this group was 61 years. Of note, the number needed to treat to prevent 1 death from prostate cancer at 10 years in this subgroup was only 5. This analysis showed that selective use of PSA screening for men in good health seems to reduce the risk for prostate cancer-specific mortality with minimal overtreatment.
Individualized screening that considers a patient's preferences and risk factors and the decision whether to confront the risks of overdiagnosis provides a balanced approach that will undoubtedly increase the diagnostic and ultimately therapeutic benefit in selected patients who choose to receive screening. Once a diagnosis is made, multidisciplinary consultation (4) TO THE EDITOR: Tsodikov and colleagues (1) seem to have resolved a long-standing controversy about the effectiveness of PSA-based screening for mortality reduction in prostate cancer-namely, the discrepancy between the ERSPC (2) and PLCO (3). They did so by applying the same analysis method (Cox regression analysis) to MLTs. Screening translated to an estimated prostate cancer mortality reduction between 25% and 31% in the ERSPC population and 27% and 32% in the PLCO population compared with no screening.
Insufficient statistical power of the ERSPC was salvaged by extending the observation period to 11 years to increase the number of deaths in the analysis. However, whether the alleged contamination bias in the PLCO was adequately controlled for is debatable, because systematic error can be remedied only before a study is launched. Discussion specifically remains on whether the sophisticated analysis of MLTs has been validated against a conventional survival analysis.
Adjusting for major confounding factors, including trial site and age, Tsodikov and colleagues noted longer MLTs in the PLCO than in the ERSPC. We thus suggest that they use an age-specific analysis involving elderly persons, because the U.S. Preventive Services Task Force does not recommend PSA screening based on a traditional analysis for persons aged 70 years or older; this recommendation differs from that for men aged 55 to 69 years, according to the discrepancy in benefitharm assessments (4) .
The effectiveness of prostate cancer mortality reduction by prostate cancer risk is of importance. The authors should show whether their findings are true for both low-risk and high-risk prostate cancer. Prostate cancer is a leading cause of cancer deaths in developed countries, and PSA testing is fraught with serious problems, including overdiagnosis and subsequent overtreatment of low-grade cancer. 
IN RESPONSE:
We appreciate the opportunity to clarify certain areas of confusion about our study of prostate cancer screening in the ERSPC and PLCO trials. Our MLT metric is a group-level measure reflecting the intensity of screening and diagnosis on each group of each trial. It aggregates groupspecific screening frequencies, PSA thresholds, and biopsy adherence into 1 measure. Of note, we do not use the MLT to determine screening benefit or as a substitute for the definitive end point of screening as Drs. Prorok and Miller suggest. Rather, our survival analysis uses an established statistical framework: Cox regression on prostate cancer survival from trial entry with group-level (MLT and trial) covariates and an interaction term. The analysis quantifies the correlation between the MLT and prostate cancer survival, and the interaction term allows us to test whether this correlation differs between trials. Because it is a group-level analysis, it does not distinguish men who were screened versus those not screened and therefore does not engender the inconsistencies suggested by Drs. Autier and Boyle or the biases that arise from different rates of disease mortality among those who decline screening and control participants as suggested by Dr. Baker.
As Drs. Prorok and Miller and Drs. Autier and Boyle note, our MLT reflects both overdiagnoses and early detections. This factor does not invalidate the MLT as a measure of screening and diagnostic intensity. More intensive screening and diagnosis probably elevate the incidence of both overdiagnosis and early detection. However, if screening leads only to overdiagnosis or to early detection without any benefit, our analysis would not show a correlation between the MLT and prostate cancer survival. Because we do find a significant correlation, and because this finding by definition cannot be due to overdiagnosis, we conclude that screening is associated with a significant survival benefit.
Drs. Prorok and Miller and Dr. Baker are concerned that we did not account for possible treatment imbalances between trial groups. We agree that such imbalances could affect our results just as they would in intention-to-treat analyses. However, evidence of imbalances in either trial is lacking. Wolters and colleagues (1) concluded that differences in the frequencies of curative treatment between the ERSPC intervention and control groups were minor after accounting for the more favorable tumor features in the intervention group. In addition, systematic differences in treatments between the ERSPC and PLCO are indirectly captured by the trial indicator in our statistical model, which was found to be statistically and clinically significant.
We agree with Dr. Baker that the absolute reduction in mortality associated with screening is important for developing sound screening policies. However, absolute reductions are sensitive to the time horizon over which they are estimated and to the baseline risk for disease-specific death. We support further work to estimate long-term absolute reductions accounting for individual patient risk factors as highlighted by Dr. Luh and associates. Our work reconciling the trials (and therefore providing 1 estimate of relative reduction instead of 2) is a step toward this objective. (2) . As long as a hospital reports its data-even if none of its patients with sepsis were treated with SEP-1 interventions-that hospital would not be penalized. A hospital's reimbursement could be altered only if it failed to report its data. The authors' claim that clinicians "must do up to 7 interventions" is materially incorrect and misrepresents both SEP-1 and the IQR Program.
Alex Tsodikov, PhD
The authors refer to SEP-1 as a performance measure that "incentivize[s] hospitals to complete all of the interventions," affecting hospital payment starting in 2018. This claim is false, and their citation to the Federal Register does not support it (3). The IQR Program is a reporting program, and a hospital's SEP-1 performance does not affect payment. If a hospital reports its data to CMS, this agency does not change that hospital's reimbursement regardless of its performance. Since SEP-1 was introduced, almost all hospitals nationally have successfully reported their data to CMS.
Pepper and colleagues' claim that The Joint Commission requires SEP-1 completion for hospital accreditation is also false. They cite a document that explicitly states that the measure is "CMS only," not a Joint Commission requirement (4) .
The title of Pepper and colleagues' review asserts that the U.S. government has "mandated" hemodynamic interventions. The Severe Sepsis and Septic Shock Early Management Bundle is a protocol-based measurement strategy for sepsis care rendered in acute care hospitals and does not "mandate" that a hospital or clinician take any specific intervention. There is no punishment, financial or otherwise, for failing to complete any action in SEP-1.
The authors incorrectly state that SEP-1 requires various hemodynamic measures, such as physical examination elements, central venous pressure measurement, dynamic assessment of volume responsiveness, and bedside cardiovascular ultrasonography. They reference the original 2015 SEP-1 specification manual (version 5.0a), which is now 3 years out of date. In more recent specification manuals from 2017, many data elements were made optional or removed (5).
Pepper and colleagues erroneously state that they evaluated the level of evidence supporting SEP-1 interventions by using the proper criteria and all relevant data. The National Quality Forum (NQF) requires that composite measures, such as SEP-1, be evaluated using specialized criteria beyond those cited in Supplement Table 1 , which was reprinted from an outdated guide from 2013 (6). The current 2017 NQF guide includes advice for composite evaluation, which permits evaluation of evidence for a group of interventions tested simultaneously, and review of program data to date (7) . The authors did not use the composite standards, reviewed interventions no longer required, and did not review program data submitted to the NQF for the 2017 reendorsement cycle.
The NQF endorsement process impanels a committee of national experts (vetted for conflicts of interest), is transparent, and includes an opportunity for an open notice and comment period to consider external expert and public feedback. In 2017, the NQF committee concluded that the level of evidence supporting the composite measure was "moderate." The measure was ultimately reendorsed with 4, 9, and 0 members evaluating the evidence as high, moderate, and low, respectively (8) . The NQF review was robust, evaluated the most up-to-date specification manual, and had input from a broad group of national experts.
IN RESPONSE:
In response to Dr. Townsend and colleagues' comment, our review has been corrected to clarify both that use of interventions in SEP-1 does not yet directly affect hospital reimbursement or accreditation and which versions of SEP-1 and CMS evidence criteria we used in our review. These revisions do not affect the review's core assertion that, after evaluating the scientific evidence underpinning SEP-1, we conclude that SEP-1 lacks high-or moderate-level evidence to support its hemodynamic interventions.
We disagree that SEP-1 is a simple, governmentmandated reporting mechanism. As an official performance measure, it is but the first step on a well-worn path that can result in government-mandated penalties affecting reimbursement and accreditation for hospitals. At the start of this slippery slope-the reporting stage-noncompliant hospitals can still be penalized. As part of the IQR Program and Inpatient Prospective Payment System, CMS collects data on whether hospitals are compliant with SEP-1 reporting (1, 2) .
One of the purposes of the IQR Program is to make compliance data available to consumers. Therefore, if CMS reports comparison data for SEP-1, hospitals may be penalized by loss of patients if CMS reports SEP-1 noncompliance. Use of SEP-1 data to compare hospital quality of care is a real possibility; although SEP-1 was not part of the comparison program in 2017, it is documented as "TBD (to be determined)" for the 2018 Hospital IQR Program measurement period (3) . As a core measure of the IQR Program, SEP-1 is a potential candidate for the CMS Value-Based Purchasing Program in which hospitals who do not complete SEP-1 would not receive CMS reimbursement (1, 4) . It could also underlie hospital accreditation. Others in the medical community share these concerns (5, 6) . For the past 2 to 3 years, SEP-1 has penalized hospitals by having them expend valuable health care provider time and other administrative resources to report interventions that lack credible supporting evidence and, according to Dr. Townsend and colleagues, have subsequently been removed from the measure.
The interventions in SEP-1 that lack credible evidence were included in the bundle's debut version in October 2015 and will continue to be included through July 2018, albeit presented in differing formats (versions 5.0a through 5.3) (Table) (7). Version 5.4, which takes effect in July 2018 (7), unfortunately still requires reporting of serial lactate measurements and fluid infusion of 30 mL/kg of body weight. Neither intervention is supported by even moderate-level evidence. Moreover, although version 5.4 requires a "volume status and tissue perfusion assessment," Dr. Townsend and colleagues do not indicate what these assessments should consist of but do reference ineffective interventions similar to those cited in prior versions (7) . This version clearly has not fully rectified the problems of previous ones.
We used the CMS level of evidence evaluation document that was in effect during our analysis. A newer document was presented in late 2017 that also describes assessment of a composite measure. The Severe Sepsis and Septic Shock Early Management Bundle is ironically an excellent example of the weakness in this assessment of a composite measure, which holds that the success of multiple interventions applied simultaneously (that is, a "bundle" of treatments) is evidence that each individual intervention is necessary for the bundle's effectiveness. For example, before the NQF endorsed SEP-1, many studies showed increased survival with bundles combining antibiotics, fluids, vasopressors, and central venous pressure and oxygen saturation measurements. On the basis of these prior studies, measurement of central venous pressure and central venous oxygen saturation were included in SEP-1 (8) . When randomized trials studied hemodynamic support directed by these measurements alone, these interventions not only were not beneficial but also increased costs (8) . (They will be removed in 2018.) We assert that using the CMS level of evidence evaluation system that we did and examining confounders for each bundle component and the overall risk of bias provides a more rigorous evaluation system to protect patients from errant science and unnecessary and unproven interventions. We are still concerned that the only study available at the time of our analysis evaluating SEP-1 in its entirety provided low-level evidence. To protect septic patients, we need reproducible, statistically significant, moderate-to highlevel evidence for individual components and components used in combination to support government reporting of SEP-1. 3 is missing, the case will proceed to a measure category assignment of X and will be rejected and processing should be stopped.
